NCT06836921

Brief Summary

Atypical Parkinsonian disorders (APD) are a group of brain disorders that look like Parkinson's disease but progress faster and don't respond well to common treatments like levodopa. These conditions include Progressive Supranuclear Palsy (PSP), Corticobasal Syndrome (CBS), and Multiple System Atrophy (MSA). Caring for APD patients is especially challenging because the symptoms worsen quickly and require multiple specialists, often leading to separate visits with different doctors and therapists. This not only increases the burden on patients and caregivers but also results in high medical costs. Despite the serious impact of APD, there is no proven care model that significantly improves the quality of life for patients and their caregivers. To address this, the investigator team has created a novel type of clinic that brings together a team of specialists in a shared appointment to provide comprehensive care in one visit. This study aims to test whether an early visit with this team, in addition to regular medical care, can improve quality of life, help patients manage their symptoms better, and reduce the stress on caregivers. The investigators will conduct a six-month study with two groups: one will receive the multidisciplinary care visit right away, while the other will continue with regular care and receive the visit after six months. Patients and caregivers will fill out questionnaires about their well-being at the beginning, after one month, and after six months. The study will also measure how practical it is to run this type of clinic, making sure enough people participate, complete the required surveys, and stay in the study. This will be the first study to test whether a team-based care model is practical and beneficial for APD patients and their caregivers. If successful, it could serve as a foundation for larger studies and potentially improve care for other complex neurological conditions in the future.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
2mo left

Started Mar 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress85%
Mar 2025Jul 2026

First Submitted

Initial submission to the registry

January 29, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

February 20, 2025

Completed
23 days until next milestone

Study Start

First participant enrolled

March 15, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2025

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2026

Expected
Last Updated

February 20, 2025

Status Verified

January 1, 2025

Enrollment Period

10 months

First QC Date

January 29, 2025

Last Update Submit

February 15, 2025

Conditions

Outcome Measures

Primary Outcomes (3)

  • Percentage of Eligible Participants Willing to be Randomized

    Definition: The proportion of eligible participants who consent to randomization in the study. Measurement: Total number of eligible participants approached for the study. Number of participants who provide informed consent and agree to be randomized. Formula: Percentage Willing=( Total Eligible Participants Approached Participants Consented and Randomized )×100

    From screening to enrollment , 12 months after study start

  • Percentage of Participants Completing Outcome Assessment

    Definition: The proportion of participants who successfully complete all required outcome assessments at designated time points. Measurement: Tracking the number of participants who complete each outcome assessment. Comparison of completion rates across different study arms. Formula: Completion Rate=(Participants Who Complete All Required Assessments Total Participants Enrolled)×100

    At 6 months after randomization

  • Satisfaction survey (Quantitative)

    Response Categories (5-point Likert scale): Very satisfied Satisfied Neutral Unsatisfied Very unsatisfied Analysis Approach: Responses will be dichotomized into: Satisfied: Very satisfied + Satisfied Not Satisfied: Neutral + Unsatisfied + Very unsatisfied The proportion of participants in each category will be calculated. Formula: Satisfaction Rate =(Satisfied Responses Total Responses)×100

    After 6 months of randomization

Study Arms (2)

Multidisciplinary clinic visit arm

EXPERIMENTAL

The multidisciplinary clinic visit will follow a shared appointment model and involve a specialized team consisting of a movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist, an occupational therapist, a speech-language pathologist, and a social worker. Care will be provided in an outpatient setting at a University Hospital. Before the initial visit, patients with APS and their care partners will complete a pre-visit questionnaire to identify their top three care priorities. During the visit, the multidisciplinary team will meet with the patient and their care partner in a single appointment room, beginning the session by addressing the identified priority issues. The team will collaboratively discuss management strategies, emphasizing self-management, and provide real-time guidance and recommendations. If needed, hands-on physiotherapy and occupational therapy evaluations will be conducted during the

Waitlist arm

OTHER

Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.

Other: Standard of Care (Investigator Choice)

Interventions

Participants in the control group will receive usual care, consisting of regular management by their neurologist, family physician, and other healthcare providers. This standard care may include referrals to community services, allied health professionals, and other support typically provided during the waitlist period for MDC visit.

Waitlist arm

The multidisciplinary clinic visit will use a shared appointment model and will include a specialized team comprising movement disorder neurologist, a palliative and critical care neurologist, a cognitive neurologist, a specialist nurse, a physiotherapist (PT), an occupational therapist (OT), a speech-language pathologist, and a social worker. Care will be delivered in an outpatient setting at a University Hospital. Prior to the initial visit, patients with APS and their care partners will receive a pre-visit questionnaire to identify their top three care priorities. During the visit, the multidisciplinary team will convene with the patient and their care partner in a single appointment room. The session will begin by addressing each of the priority issues identified by the patient and care partner. The team will collaboratively discuss management strategies, focusing on self-management, and will provide real-time guidance and recommendations. As indicated, hands-on PT and OT evaluatio

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants must be older than 40 years.
  • The participant must meet the standard international consensus criteria for a clinically probable diagnosis of one of the following neurodegenerative conditions:Multiple System Atrophy (MSA);Progressive Supranuclear Palsy (PSP);Cortico-Basal Syndrome (CBS)

You may not qualify if:

  • Severe Physical or Cognitive Limitations:
  • Participants must be able to attend the clinic.
  • Individuals with severe physical disabilities or cognitive impairments that prevent clinic attendance will be excluded.
  • Life-Threatening Comorbidities:
  • Participants with severe, advanced medical conditions that significantly impact survival or functional ability will be excluded. These include, but are not limited to:End-stage renal disease (ESRD) requiring dialysis; End-stage congestive heart failure (CHF) with severe functional impairment; Advanced malignancy (such as metastatic cancer or terminal cancer with limited prognosis).
  • Living in long-term care, away from the care-partner

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health CareQuality of Health CareHealth Services AdministrationHealth Care Quality, Access, and Evaluation

Central Study Contacts

Deepa Dash, MD, DM

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

January 29, 2025

First Posted

February 20, 2025

Study Start

March 15, 2025

Primary Completion

December 31, 2025

Study Completion (Estimated)

July 20, 2026

Last Updated

February 20, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share